Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.91 1.28 +1.79%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated (CORT) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 1 added · 2 removed · 45 modified
P2I1A: 5 added · 7 removed · 76 modified
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 22, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
10-Q Jun 30, 2026 P1I2: 5 added · 3 removed · 36 modified
P2I1A: 5 added · 3 removed · 43 modified
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jun 17, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 19, 2026 8.01 Other events
8-K May 21, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 25, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 76 added · 9 removed · 56 modified
1A: 31 added · 3 removed · 57 modified
7: 19 added · 4 removed · 41 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 19, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 22, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
8-K Oct 10, 2025 1.02 Termination of a material definitive agreement; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Sep 10, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 31, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
10-Q Mar 31, 2025
8-K May 5, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 26, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 29, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 8, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.